Tampa Bay Business Journal Highlights Innovation Hub<SUP>SM</SUP> for NextGen Manufacturers

10 June 2012

Foley & Lardner Unveils Innovation Hub for Manufacturers

June 10, 2013
By Jane Meinhardt

Foley & Lardner LLP has launched Legal Innovation HubSM for NextGen Manufacturers to help clients facing the convergence of technology and manufacturing.

The initiative involves a firm-wide network of departments, industry teams and practice groups, according to a written statement.

The firm’s office in Tampa will be directly involved in the Foley Legal Innovation Hub.

Foley will partner with consulting firms, academia, government and industry associations in addition to using think tanks, social media platforms and roundtable discussions to assist manufacturing clients.

Nearly a third of the firm’s top 1,000 clients are in the manufacturing sector.

Florida has about 18,000 manufacturers employing 311,300 people. Pinellas County leads the Tampa Bay region in manufacturing employment with more than 30,000 employees.

Click here to access the article on the Tampa Bay Business Journal Web site.

Sectors

Manufacturing

Related News

View All Posts

25 July 2024 In the News

Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’

Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”

24 July 2024 In the News

Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO

Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.

24 July 2024 In the News

Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’

Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”